Morikiri Y, Matsuta E, Inoue H
On Day 61 or thereafter, if: (2.3) o No additional glycemic control is needed, maintain the dosage at 4 mg orally once daily
Injection-Based Administration Subcutaneous injections: All GLP-1 RAs are administered via subcutaneous injection Prefilled pens: Most common delivery system, allows for self-administration Auto-injectors: Simplify the process for patients with dexterity issues Multi-dose pens: Require dose dialing and needle attachment Dosing frequency: Daily: Liraglutide (Saxenda, Victoza), some formulations of exenatide (Byetta) Weekly: Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide extended-release (Bydureon) Titration schedules: Most FDA-approved GLP-1 RAs require gradual dose escalation to minimize gastrointestinal side effects
This makes them much better suited to treatment compliance than addiction therapies which require daily administration (and it should be noted that several longer acting formulations of existing SUD medications are coming to market as well)
Patients who pair it with meaningful lifestyle changes, such as healthier eating habits and regular exercise, achieve better and more sustainable results
Taylor, R